National Services Division

All Labs Somatic Cancer Testing

24 October 2021



Discussion

- Analysis based on all Labs (Aberdeen, Dundee Edinburgh and Glasgow) 2019-2020 data provided for Somatic Testing for Solid Tumours and Haematological Malignancies,
  - Germline testing has been analysed and provided separately,
- Data Analysis to consider how current **activity** could be illustrated and support future capacity planning for the SGLC service and potential what-if scenarios based on future and changing demand requirements.

All Labs Somatic Testing 2019 – 2020 Samples In



All Lab Somatic Testing 2019 – 2020 Samples In by Type and Disease 1



All Lab Somatic Testing 2019 – 2020 Samples In by Type and Disease 2



All Samples Somatic Cancer Testing Samples In 2019 - 2020



All Samples In – by Type and Lab 2019 - 2020



All Labs Number of Test Methods Applied



Number of Test Methods applied – Solid Tumours and Haematological Malignancies



All Labs Number of Test Types Applied



All Labs Solid Tumours Samples In by Disease



All Labs Haematological Malignancies Samples In by Disease



All Labs Somatic Testing – Activity for Solid Tumours 1



All Labs Somatic Testing – Activity for Solid Tumours 2



All Labs Somatic Testing – Activity for Haematological Malignancies 1



All Labs Somatic Testing – Activity for Haematological Malignancies 2



Discussion

- Complexity and duration of tests is not considered at this point in the analysis,
- Analysis does not consider resources or equipment required to meet demand,
- There are clear and distinct patterns in the data related to the “volume” of activity,
- Not to confuse high volume of samples with relatively few, shorter tests and low volumes of samples with higher numbers of longer tests and complexity,
- Workload should be considered as a function of the number of samples, tests and reports which can all be quantified,
- TATs not analysed at this point,
- Explore explicit link to Outcomes for Patients for different Categories and Types.